Heart failure congress sets new record for original science submissions

March 29, 2017

Sophia Antipolis 29 March 2017. A new record for original science submissions has been set for the world's leading heart failure congress. In addition to the main abstract programme, highly anticipated results from major studies will be presented in the late breaking trial sessions.

Authors from the across the globe sent nearly 2 000 abstracts to the scientific committee of Heart Failure 2017 and the 4th World Congress on Acute Heart Failure. The main annual meeting of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) takes place from 29 April to 2 May at the Palais des Congrès in Paris, France.

The full scientific programme is available here

"No other meeting has had so much new research presented in heart failure," said Professor Alexandre Mebazaa, Heart Failure 2017 Scientific Chairperson. "Companies and major academic centres are eager to present results of their latest trials at this congress which is a good sign that it is the place to present new work in this field."

Controversial issues will be tackled by top cardiologists in the new Grand Debates sessions, giving members of the press both sides of the story. Professor Eugene Braunwald will introduce the first session on LCZ696 (sacubitril/valsartan), and Professor John McMurray and Professor Mariell Jessup will battle out whether it is ready for prime time as first-line therapy.

The 50th anniversary of heart transplantation will be marked with dedicated sessions. Leaders in the field will explore the limits to heart transplantation, present the latest research on immunosuppression and rejection, and ask "Will we ever be able to cure heart failure"?

The congress tagline "rendez-vous with the future" emphasises the 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure1 as the new standard of care and puts the spotlight on young cardiologists, represented by the Heart failure specialists of Tomorrow (HoTs).

"We used to publish guidelines and that was the end of the story," said Professor Mebazaa. "This year we will give practical examples of how physicians can implement the best knowledge into their daily practice. HoT members will challenge the application of the guidelines - journalists interested in challenging current practice should not miss these sessions."

The second annual HoT Walk will take place on the evening of Monday 1 May. Members of the public are invited to join the HFA, French Federation of Cardiology, and French Society of Cardiology for a 3 km walk through the streets of Paris.

The HFA Lifetime Achievement Award will be bestowed on two prominent cardiologists during the Inaugural Session and each will give a keynote lecture. In the HFA Philip Poole Wilson Lecture, Professor Faiez Zannad will reveal the next frontier for mineralocorticoid receptor antagonists, while Professor Michel Komajda will devote the HFA Eugene Braunwald Lecture to the topic "Heart failure and diabetes mellitus: les liaisons dangereuses".

ESC Gold Medalist and cardiac surgery pioneer Professor Alain Carpentier will talk about the total artificial heart he invented in the session "Allez les Bleus! Groundbreaking French contributions to cardiology".

Professor Mebazaa said: "This is the event of the year in heart failure and members of the media should mark their calendars. The World Congress on Acute Heart Failure will showcase novel results from large trials on new drugs. Heart Failure 2017 will give the state-of-the-art on the hot topic of preventing heart failure, as research has shown that the heart's malfunction leads to many other diseases. We will also hear the latest findings on treating women and men, who we now know need tailored therapies."

Some 6 000 delegates are set to attend the four day event which features 120 scientific sessions. Journalists are highly recommended to register now.
-end-


European Society of Cardiology

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.